<DOC>
	<DOCNO>NCT02279602</DOCNO>
	<brief_summary>Subjects achieve clinical response study OX4218s biomarker reduction symptom response eligible enroll rollover study continue every three week fosbretabulin infusion one year .</brief_summary>
	<brief_title>Rollover Protocol Subjects Who Have Responded Study 4218s - A Phase 2 Study</brief_title>
	<detailed_description>Subjects enrol PNET/GI-NET study OX4218s receive weekly dose fosbretabulin 3 cycle approximately 9 week . Subjects achieve clinical response biomarker reduction symptom response base investigator assessment eligible enroll rollover study ( protocol OX4219s ) . Subjects receive fosbretabulin every three week maximum approximately one year disease progression , unacceptable toxicity , consent withdrawal , protocol-noncompliance , investigator feel longer subject 's best interest continue therapy .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>Subject treat OXiGENEsponsored Phase 2 study OX4218s Subject receive fosbretabulin treatment study OX4218s</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Gastrointestional</keyword>
</DOC>